Atea Pharmaceuticals, Inc. (AVIR) Cash Flow Statement
Atea Pharmaceuticals, Inc. (AVIR) generated -$152.1M of operating cash flow over the twelve months to 2026-06-30, spent $0 on capital expenditure and had free cash flow of -$152.1M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AVIRAtea Pharmaceuticals, Inc.Follow AVIR — free
—
Price chart with a free account
- Market cap
- 324.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 296.7 | -87.0 | -121.0 | -85.4 | -135.5 | -132.0 | -152.1 | |
| Capital expenditure | 0.0 | 0.0 | 1.9 | — | 0.0 | 0.0 | -0.0 | |
| Free cash flow | 296.7 | -87.0 | -122.9 | — | -135.5 | -132.0 | -152.1 | |
| Share repurchases | — | — | — | — | 0.0 | 25.5 | — | |
| Stock-based compensation | 7.5 | 39.6 | 46.7 | 49.4 | 51.8 | 20.7 | — |
USD millions · SEC XBRL
Atea Pharmaceuticals, Inc. — questions
- What is Atea Pharmaceuticals, Inc.'s operating cash flow?
- -$152.1M over the twelve months to 2026-06-30.
- How much does Atea Pharmaceuticals, Inc. spend on capital expenditure?
- $0 over the twelve months to 2026-06-30.
- What is Atea Pharmaceuticals, Inc.'s free cash flow?
- -$152.1M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Atea Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.